---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-104135"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:39:16.628044+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Korro Bio reports FY2025 net loss $117.3M, nominates KRRO-121 for UCD/HE; $85M PIPE extends runway to H2 2028

## Summary
- FY2025 net loss $117.3M vs $83.6M in FY2024, driven by $30.9M non-cash impairment charges on KRRO-110 termination.
- Cash $85.2M at Dec 31, 2025; plus $85M private placement in Mar 2026 extends runway into H2 2028.
- Nominated KRRO-121 for UCD and HE; regulatory filing expected H2 2026.
- GalNAc AATD program achieved >90% in vivo RNA editing; candidate nomination Q2 2026.
- Collaboration revenue $6.4M from Novo Nordisk (paused); R&D expenses $65.6M, G&A $28.2M.

## SEC filing metadata
- accession: 0001193125-26-104135
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312526104135/0001193125-26-104135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312526104135/krro-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-104135
- JSON: https://secwatch.observer/filing/0001193125-26-104135.json
- Plain text: https://secwatch.observer/filing/0001193125-26-104135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.